What 29 Analyst Ratings Have To Say About Biogen
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 29 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. The company has an average price target of $324.41, up by 3.15% from the previous average price target of $314.50. The majority of the ratings are bullish.
July 07, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen has received mostly bullish ratings from 29 analysts over the past 3 months. The average price target has increased by 3.15% to $324.41.
The majority of the 29 analysts have given bullish ratings to Biogen, indicating a positive outlook for the company's stock. The increase in the average price target also suggests that analysts expect the stock price to rise in the future. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100